CG Oncology (CGON) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
24 Apr, 2026Executive summary
Annual meeting scheduled for June 4, 2026, to be held virtually for shareholder participation.
Proxy materials, including the Notice of Meeting, Proxy Statement, and Annual Report, are available online, with paper copies available upon request by May 25, 2026.
Voting matters and shareholder proposals
Election of two Class II director nominees, Christina Rossi and Victor Tong, Jr., to serve until the 2029 Annual Meeting.
Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Advisory vote to approve compensation of Named Executive Officers.
Advisory vote on the preferred frequency (every 1 year) of stockholder advisory votes on executive compensation.
Board of directors and corporate governance
Board recommends voting for all director nominees and for all proposals, including annual say-on-pay frequency.
Latest events from CG Oncology
- Pivotal NMIBC trial results and regulatory filings position cretostimogene for first approval.CGON
Goldman Sachs 47th Annual Global Healthcare Conference 20269 Jun 2026 - Cretostimogene shows durable efficacy and safety in NMIBC, with pivotal data and launch prep ongoing.CGON
Jefferies Global Healthcare Conference 20263 Jun 2026 - Cretostimogene advances toward broad NMIBC use with strong data, scalable manufacturing, and launch prep.CGON
RBC Capital Markets Global Healthcare Conference 202620 May 2026 - Janus IPO and portfolio strategy drive Healthpeak’s growth and value creation across healthcare real estate.CGON
Bank of America Global Healthcare Conference 202612 May 2026 - Net loss rose to $60.2M with $1.1B cash, supporting clinical milestones through 2029.CGON
Q1 20268 May 2026 - Shareholders will vote on directors, auditor, executive pay, and annual say-on-pay frequency.CGON
Proxy filing24 Apr 2026 - Credo shows high efficacy and durability, with regulatory and commercial plans advancing.CGON
TD Cowen 46th Annual Health Care Conference2 Mar 2026 - Cretostimogene delivers leading efficacy and safety in NMIBC, advancing toward market launch.CGON
Investor presentation27 Feb 2026 - 2025 net loss widened to $161M as R&D ramped up, with $903M cash to fund operations into 2029.CGON
Q4 202527 Feb 2026